Promising early results for treating metastatic prostate cancer
https://www.facingourrisk.org/XRAY/talazoparib-for-metastatic-prostate-cancer
Full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00376-4/fulltext
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- With my diagnosis of mCRPC, should I consider genetic testing for an inherited mutation?
- Should I have additional tumor testing to see what other treatments may be available for me?
- What are the treatment options for my metastatic prostate cancer?
- Is PARP inhibitor therapy appropriate for me? Am I eligible for any clinical trials of PARP inhibitors?
Open Clinical Trials
The following treatment studies are enrolling people with advanced prostate cancer:
- NCT05011383: High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation. This study will examine how well an increased dose of testosterone treatment works for people with metastatic castration-resistant prostate cancer (mCRPC) with an ATM, CDK12, or CHEK2 genetic mutation.
- NCT04249947: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC). This study is looking at treatment using a type of immunotherapy known as CAR-T for treating metastatic prostate cancer that expresses PSMA.
- NCT05367440: Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 Combined With Hormone Therapy. This study will look at the effectiveness of a new PARP inhibitor drug called AZD5305 in combination with different hormone therapies to treat metastatic prostate cancer, compared to the current standard treatment.
- NCT04038502: Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA). This study is comparing carboplatin chemotherapy to the PARP inhibitor, olaparib as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L mutation.
-
NCT06120491: Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options for Metastatic Prostate Cancer EvoPAR-PRO1. This study will evaluate an investigational PARP inhibitor drug called Saruparib in combination with new hormonal agents to treat metastatic prostate cancer compared to standard treatment in people whose tumors have a mutation in: BRCA1, BRCA2, ATM, BARD1, CDK12, PALB2, RAD51B, RAD51C, or RAD51D.
The following studies are enrolling people with advanced solid tumors, including prostate cancer:
- NCT06545942: Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib. This trial will study MOMA-313 given alone or together with a PARP inhibitor (olaparib) in people with certain advanced or metastatic cancers with the following mutations: ATM, BRCA1, BRCA2, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and/or RAD54L.
- NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study examines the safety and effectiveness of the investigational treatment XL309 when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors, including prostate cancer.
- NCT05417594: Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study). This study looks at a new PARP inhibitor AZD9574 given alone and in combination with other anti-cancer drugs for people with advanced cancer that has come back or progressed.
Other clinical trials for people with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.